BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 17125442)

  • 1. Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
    Shapiro NL; Durr EA; Krueger CD
    Pharmacotherapy; 2006 Dec; 26(12):1806-10. PubMed ID: 17125442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
    Hursting MJ; Lewis BE; Macfarlane DE
    Clin Appl Thromb Hemost; 2005 Jul; 11(3):279-87. PubMed ID: 16015413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
    Bartholomew JR; Hursting MJ
    J Thromb Thrombolysis; 2005 Jun; 19(3):183-8. PubMed ID: 16082605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of argatroban as a procedural and bridging anticoagulant in a patient undergoing carotid endarterectomy with concomitant atrial fibrillation.
    Nanda MM; Kauflin MJ; Jain PG; Yannetta JC
    Ann Pharmacother; 2011 Mar; 45(3):e16. PubMed ID: 21386022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.
    Burger CF; Schlesinger JJ
    Ann Pharmacother; 2014 Feb; 48(2):286-91. PubMed ID: 24259642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban anticoagulation in critically ill patients.
    Beiderlinden M; Treschan TA; Görlinger K; Peters J
    Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
    Hursting MJ; Verme-Gibboney CN
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose argatroban for treatment of heparin-induced thrombocytopenia with thrombosis: a case report and review of laboratory considerations.
    Hellwig TR; Peitz GJ; Gulseth MP
    Am J Health Syst Pharm; 2012 Mar; 69(6):490-5. PubMed ID: 22382479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal Prolongation of Prothrombin Time with Extended Exposure to Argatroban.
    McAlister RK; Ito S
    Pharmacotherapy; 2015 Jul; 35(7):e122-6. PubMed ID: 26147471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE; White RH
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin.
    Sheth SB; DiCicco RA; Hursting MJ; Montague T; Jorkasky DK
    Thromb Haemost; 2001 Mar; 85(3):435-40. PubMed ID: 11307810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of heparin-induced thrombocytopenia associated with unexpected excessive argatroban anticoagulation after abdominal aortic aneurysm resection].
    Ichikawa M; Oue M; Okamoto A; Morishita H; Minatoya K; Ogino H; Miyata S; Imanaka H
    Masui; 2006 Feb; 55(2):188-92. PubMed ID: 16491897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.
    Hursting MJ; Soffer J
    Drug Saf; 2009; 32(3):203-18. PubMed ID: 19338378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-induced thrombocytopenia from venous thromboembolism treatment.
    Begelman SM; Hursting MJ; Aghababian RV; McCollum D
    J Intern Med; 2005 Dec; 258(6):563-72. PubMed ID: 16313480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.